Novel Treatments and New Research in Hodgkin Lymphoma

News
Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

In this video interview, Joseph Connors gives an overview of the results presented here at ASCO of the phase II trial of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma, and discusses the most intriguing work currently being done with novel agents used to treat relapsed or refractory Hodgkin lymphoma.

In this video Cancer Network interviews Dr. Joseph Connors, clinical director at the Centre for Lymphoid Cancer, BC Cancer Agency, and Clinical Professor, University of British Columbia, Vancouver.

Dr. Connors gives an overview of the results presented here at ASCO of the phase II trial of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma, and discusses the most intriguing work currently being done with novel agents used to treat relapsed or refractory Hodgkin lymphoma.

Recent Videos
No evidence indicates synergistic toxicity when combining radiation with CAR T-cell therapy in this population, according to Timothy Robinson, MD, PhD.
The addition of radiotherapy to CAR T-cell therapy may particularly benefit patients with localized disease, according to Timothy Robinson, MD, PhD.
Timothy Robinson, MD, PhD, discusses how radiation may play a role as bridging therapy to CAR T-cell therapy for patients with relapsed/refractory DLBCL.
Pallawi Torka, MD, with the Oncology Brothers presenting slides
Pallawi Torka, MD, with the Oncology Brothers presenting slides
Pallawi Torka, MD, with the Oncology Brothers presenting slides
Pallawi Torka, MD, with the Oncology Brothers presenting slides
Carla Casulo, MD, with the Oncology Brothers presenting slides
Carla Casulo, MD, with the Oncology Brothers presenting slides
Carla Casulo, MD, with the Oncology Brothers presenting slides
Related Content
Phase 3 data show that nivolumab/AVD may also reduce long-term toxicities vs brentuximab vedotin/AVD in advanced Hodgkin lymphoma.

Nivolumab Combo Improves PFS in Stage III/IV Advanced Hodgkin Lymphoma

Russ Conroy
October 17th 2024
Article

Phase 3 data show that nivolumab/AVD may also reduce long-term toxicities vs brentuximab vedotin/AVD in advanced Hodgkin lymphoma.

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Leveraging Ex Vivo Gene Therapy Advancements in Hemoglobinopathies and Metabolic Diseases

Alexis K. Kuhn, PharmD, BCOP ;Katie Bruce, PharmD, BCPPS;Susie Long, PharmD
October 21st 2024
Podcast

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Calcineurin inhibition rescues alloantigen-specific central memory T cell subsets that promote chronic GVHD

Calcineurin inhibition rescues alloantigen-specific central memory T cell subsets that promote chronic GVHD

American Society for Transplantation and Cellular Therapy
September 26th 2024
Article

These findings demonstrate the potential risks associated with CNI-based immunosuppression in stem cell transplantation without concurrent strategies to eliminate alloreactive T cells.

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

Managing Secondary Cancer Risks After CAR T-Cell Therapy in Multiple Myeloma Subgroups

Rahul Banerjee, MD, FACP;Noopur Raje, MD
September 2nd 2024
Podcast

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

Complete responses were observed in a small cohort of patients with DLBCL who have previously received autologous CAR T-cell therapy.

Azer-Cel Achieves Complete Responses in Relapsed/Refractory DLBCL

Harrison Widelitz
September 18th 2024
Article

Complete responses were observed in a small cohort of patients with DLBCL who have previously received autologous CAR T-cell therapy.

Treatment with valemetostat yields responses across all PTCL subtypes in the phase 2 VALENTINE-PTCL01 trial.

Valemetostat Shows Meaningful Benefit in Peripheral T-Cell Lymphoma

Chris Ryan
September 10th 2024
Article

Treatment with valemetostat yields responses across all PTCL subtypes in the phase 2 VALENTINE-PTCL01 trial.